Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions

被引:8
|
作者
Beygi, Mohammad [1 ]
Ahi, Salma [2 ]
Zolghadri, Samaneh [3 ]
Stanek, Agata [4 ]
机构
[1] Isfahan Univ Technol IUT, Coll Agr, Dept Agr Biotechnol, Esfahan 8415683111, Iran
[2] Jahrom Univ Med Sci, Res Ctr Noncommunicable Dis, Jahrom 7414846199, Iran
[3] Islamic Azad Univ, Dept Biol, Jahrom Branch, Jahrom 7414785318, Iran
[4] Med Univ Silesia, Fac Med Sci Zabrze, Dept Internal Med Angiol & Phys Med, Batorego 15 St, PL-41902 Bytom, Poland
关键词
fatty liver disease; nutrition; lifestyle; cardiovascular diseases; diabetes; obesity; TYPE-2; DIABETES-MELLITUS; PHYSICAL-ACTIVITY; WEIGHT-LOSS; DIET; CARBOHYDRATE; MECHANISMS; EXERCISE; MAFLD; NAFLD;
D O I
10.3390/nu16142220
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting liver disease that affects millions of people around the world. It is best identified with a hepatic fat build-up that ultimately leads to inflammation and damage. The classification and nomenclature of NAFLD have long been a controversial topic, until 2020 when a group of international experts recommended substituting NAFLD with MAFLD (metabolic dysfunction-associated FLD). MAFLD was then terminologically complemented in 2023 by altering it to MASLD, i.e., metabolic dysfunction-associated steatotic liver disease (MASLD). Both the MAFLD and the MASLD terminologies comprise the metabolic element of the disorder, as they offer diagnostic benchmarks that are embedded in the metabolic risk factors that underlie the disease. MASLD (as a multisystemic disease) provides a comprehensive definition that includes a larger population of patients who are at risk of liver morbidity and mortality, as well as adverse cardiovascular and diabetes outcomes. MASLD highlights metabolic risks in lean or normal weight individuals, a factor that has not been accentuated or discussed in previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, and exercise therapies have not been extensively studied in MAFLD and MASLD. Nutrition plays a vital role in managing both conditions, where centralizing on a diet rich in whole vegetables, fruits, foods, healthy fats, lean proteins, and specific nutrients (e.g., omega-3 fatty acids and fibers) can improve insulin resistance and reduce inflammation. Thus, it is essential to understand the role of nutrition in managing these conditions and to work with patients to develop an individualized plan for optimal health. This review discusses prevention strategies for NAFLD/MAFLD/MASLD management, with particular attention to nutrition and lifestyle correction.
引用
收藏
页数:25
相关论文
共 50 条
  • [31] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [32] Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease
    Savytska, Maryana
    Baka, Olena
    Manzhalii, Elina
    Kyriienko, Dmytro
    Falalyeyeva, Tetyana
    Zhayvoronok, Maksym
    Kovalchuk, Oleksandr
    Deresh, Nataliya
    Grygoriev, Fedir
    Kobyliak, Nazarii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S610 - S611
  • [33] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [34] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [35] Vitamin E in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (02) : 551 - 552
  • [36] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [37] METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH LIVER FIBROSIS IN HEPATITIS C
    Elgretli, Wesal
    Shengir, Mohamed
    Sasson, Solomon
    Agnihotram, V. Ramanakumar
    Ballesteros, Luz Esther Ramos
    Deschenes, Marc
    Wong, Philip
    Chen, Tianyan
    Kronfli, Nadine
    Keeshan, Alexa
    Tandon, Saniya
    Cooper, Curtis
    Sebastiani, Giada
    HEPATOLOGY, 2024, 80 : S382 - S383
  • [38] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [39] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [40] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019